(25)
August 04 2017 - 7:01AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 25
NOTIFICATION OF REMOVAL FROM LISTING
AND/OR
REGISTRATION UNDER SECTION 12(b) OF THE
SECURITIES EXCHANGE ACT OF 1934.
Commission File Number
001-32715
Interleukin
Genetics, Inc.
OTCQB
(Exact name of Issuer as specified in its
charter, and name of Exchange where security is listed and/or registered)
135 Beaver Street
Waltham, MA 02452
(781) 398-0700
(Address, including zip code, and telephone
number, including area code, of Issuer's principal executive offices)
All authorized Preferred and Common stock
(Description of class of securities)
Please place an X in the box to designate the rule provision
relied upon to strike the class of securities from listing and registration:
|
¨
|
17
CFR 240.12d2-2(a)(1)
|
|
¨
|
17
CFR 240.12d2-2(a)(2)
|
|
¨
|
17
CFR 240.12d2-2(a)(3)
|
|
¨
|
17
CFR 240.12d2-2(a)(4)
|
|
¨
|
Pursuant
to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw
registration on the Exchange.
1
|
|
x
|
Pursuant
to 17 CFR 240.12d2-2(c), the Issuer has complied with the rules of the Exchange and the requirements of 17 CFR 240.12d2-2(c) governing
the voluntary withdrawal of the class of securities from listing and registration on the Exchange.
|
|
1
|
Form 25 and attached notice will be considered compliance
with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.
|
Pursuant to the requirements of the Securities Exchange Act
of 1934, Interleukin Genetics, Inc. certifies that it has reasonable grounds to believe that it meets all of the requirements for
filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.
Date: August 4, 2017
|
|
By:
|
/s/ Barry Kallander
|
|
|
|
|
Title
|
President
|
|
|